Moderna (MRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tyler Van Buren ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...

Moderna (MRNA) stock gains as company posts better than expected Q3 results driven by its updated COVID-19 vaccine. Read more ...

2024年11月7日，Moderna公司打破了市场预期，公布了其2024年第三季度财报，收入达到19亿美元，较去年同期增长3.5%。这一业绩的背后，除了组织运营的成功管理，更重要的是其新冠疫苗Spikevax的出色表现。然而，尽管在财报中取得了意外的成功，这份喜悦却伴随着不可忽视的警示和市场竞争的压力。 全球新冠疫苗市场的现状 自COVID-19疫情开始以来，新冠疫苗市场经历了迅猛的发展。在这一领 ...

智通财经APP获悉，周三，美国西北大学(Northwestern University)在特拉华州联邦法院对Moderna(MRNA.US)提起了一项新的专利诉讼，指控该公司滥用该校的创新成果来开发其重磅的新冠疫苗Spikevax。

Moderna reported a surprising third-quarter profit on Thursday, driven by cost reductions and stronger-than-expected sales of ...

MRNA reports better-than-expected third-quarter earnings. It reiterates the guidance of product sales to between $3 billion ...

Moderna's new version of its COVID-19 vaccine, which targets two virus variants including Omicron, has outperformed the company's original Spikevax shot in a head-to-head clinical trial.